| Stage | EMR | % of rev | GE | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $4.9B | 100.00% | $14.1B | 100.00% | GE ×2.90 |
| Gross profit | $2.7B | 54.48% | $5.0B | 35.57% | EMR +18.9pp |
| Operating income | $1.0B | 20.54% | $2.6B | 18.45% | EMR +2.1pp |
| Pre-tax income | $916M | 18.80% | $2.8B | 19.87% | GE +1.1pp |
| Net income | $718M | 14.73% | $2.3B | 16.26% | GE +1.5pp |
| Stage | EMR | GE | Gap · A − B |
|---|---|---|---|
| Revenue | $4.9B100.00% | $14.1B100.00% | GE ×2.90 |
| Gross profit | 54.48%$2.7B | 35.57%$5.0B | EMR +18.9pp |
| Operating income | 20.54%$1.0B | 18.45%$2.6B | EMR +2.1pp |
| Pre-tax income | 18.80%$916M | 19.87%$2.8B | GE +1.1pp |
| Net income |
| 14.73%$718M |
| 16.26%$2.3B |
| GE +1.5pp |
None
No disclosed counterparties: EMR.